Skip to main content

ErbB4 and its Isoforms: Patentable Drug Targets?

Buy Article:

$105.00 plus tax (Refund Policy)

Research on ErbB receptors has spearheaded the rational cancer drug design, and ErbB1 (also known as EGFR) and ErbB2 are among the first clinically validated targeted therapies. Despite the fact that applicability of ErbB4 as a drug target is still uncertain, several patents involving utilization of ErbB4 have recently been issued. Manipulation of functions of ErbB4 may be therapeutically beneficial in cancer but also in psychiatric and cardiovascular disorders. In addition, analyzing expression or mutations of ErbB4 may provide prognostic or predictive value. Contents of ErbB4- related patents, as well as biology of ErbB4 and its alternatively spliced isoforms, will be reviewed in this article.





No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Cancer; HER; heart disease; neuregulins; receptor tyrosine kinases; schizophrenia; therapeutics

Document Type: Research Article

Publication date: 2008-01-01

More about this publication?
  • Recent Patents on DNA and Gene Sequences publishes review articles by experts on recent patents on DNA and gene sequences. A selection of important and recent patents in the field is also included in the journal. The journal is essential reading for all researchers involved in applied molecular biology.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more